<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p247" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_247{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_247{left:306px;bottom:30px;}
#t3_247{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_247{left:346px;bottom:30px;}
#t5_247{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_247{left:517px;bottom:30px;}
#t7_247{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_247{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_247{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_247{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_247{left:35px;bottom:777px;letter-spacing:0.07px;word-spacing:0.12px;}
#tc_247{left:35px;bottom:759px;letter-spacing:0.11px;word-spacing:0.07px;}
#td_247{left:35px;bottom:739px;letter-spacing:0.02px;word-spacing:-0.86px;}
#te_247{left:35px;bottom:720px;letter-spacing:0.1px;word-spacing:0.08px;}
#tf_247{left:35px;bottom:700px;letter-spacing:0.16px;}
#tg_247{left:405px;bottom:700px;}
#th_247{left:35px;bottom:665px;letter-spacing:0.12px;word-spacing:0.07px;}
#ti_247{left:35px;bottom:645px;letter-spacing:0.1px;word-spacing:0.08px;}
#tj_247{left:35px;bottom:625px;letter-spacing:0.11px;word-spacing:0.08px;}
#tk_247{left:35px;bottom:606px;letter-spacing:0.16px;}
#tl_247{left:405px;bottom:606px;}
#tm_247{left:35px;bottom:570px;letter-spacing:0.06px;word-spacing:0.12px;}
#tn_247{left:35px;bottom:551px;letter-spacing:0.05px;word-spacing:-0.82px;}
#to_247{left:35px;bottom:531px;letter-spacing:0.1px;word-spacing:0.09px;}
#tp_247{left:35px;bottom:512px;letter-spacing:0.09px;word-spacing:0.1px;}
#tq_247{left:35px;bottom:492px;letter-spacing:0.16px;}
#tr_247{left:405px;bottom:492px;}
#ts_247{left:35px;bottom:457px;letter-spacing:0.05px;word-spacing:0.13px;}
#tt_247{left:35px;bottom:437px;letter-spacing:0.1px;word-spacing:0.08px;}
#tu_247{left:35px;bottom:418px;letter-spacing:0.07px;word-spacing:0.11px;}
#tv_247{left:35px;bottom:398px;word-spacing:-0.77px;}
#tw_247{left:35px;bottom:379px;letter-spacing:-0.38px;}
#tx_247{left:59px;bottom:379px;letter-spacing:0.16px;}
#ty_247{left:428px;bottom:379px;}
#tz_247{left:35px;bottom:343px;letter-spacing:0.04px;word-spacing:0.15px;}
#t10_247{left:35px;bottom:324px;letter-spacing:0.11px;word-spacing:0.07px;}
#t11_247{left:35px;bottom:304px;letter-spacing:0.02px;word-spacing:0.17px;}
#t12_247{left:35px;bottom:284px;letter-spacing:0.07px;word-spacing:-1.01px;}
#t13_247{left:35px;bottom:266px;letter-spacing:0.08px;word-spacing:0.1px;}
#t14_247{left:35px;bottom:247px;letter-spacing:0.15px;}
#t15_247{left:548px;bottom:247px;}
#t16_247{left:35px;bottom:210px;letter-spacing:0.12px;word-spacing:-0.31px;}
#t17_247{left:35px;bottom:190px;letter-spacing:0.11px;word-spacing:-0.2px;}
#t18_247{left:35px;bottom:172px;letter-spacing:0.09px;word-spacing:-0.69px;}
#t19_247{left:35px;bottom:152px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1a_247{left:35px;bottom:133px;letter-spacing:0.16px;}
#t1b_247{left:396px;bottom:133px;}
#t1c_247{left:35px;bottom:96px;word-spacing:0.18px;}
#t1d_247{left:35px;bottom:78px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1e_247{left:35px;bottom:58px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1f_247{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1g_247{left:618px;bottom:759px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1h_247{left:618px;bottom:739px;letter-spacing:0.16px;}
#t1i_247{left:988px;bottom:739px;}
#t1j_247{left:618px;bottom:702px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1k_247{left:618px;bottom:683px;letter-spacing:0.01px;word-spacing:-0.9px;}
#t1l_247{left:618px;bottom:665px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1m_247{left:618px;bottom:645px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1n_247{left:618px;bottom:625px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1o_247{left:618px;bottom:606px;letter-spacing:0.16px;}
#t1p_247{left:988px;bottom:606px;}
#t1q_247{left:618px;bottom:570px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1r_247{left:618px;bottom:551px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1s_247{left:618px;bottom:531px;word-spacing:0.18px;}
#t1t_247{left:618px;bottom:512px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1u_247{left:618px;bottom:492px;letter-spacing:0.16px;}
#t1v_247{left:988px;bottom:492px;}
#t1w_247{left:618px;bottom:457px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1x_247{left:618px;bottom:437px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1y_247{left:618px;bottom:418px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t1z_247{left:618px;bottom:398px;letter-spacing:0.1px;word-spacing:0.09px;}
#t20_247{left:618px;bottom:379px;letter-spacing:0.16px;}
#t21_247{left:988px;bottom:379px;}
#t22_247{left:618px;bottom:343px;letter-spacing:0.03px;word-spacing:-0.77px;}
#t23_247{left:618px;bottom:324px;letter-spacing:0.09px;word-spacing:0.09px;}
#t24_247{left:618px;bottom:304px;letter-spacing:0.06px;word-spacing:0.12px;}
#t25_247{left:618px;bottom:284px;letter-spacing:0.18px;}
#t26_247{left:618px;bottom:265px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t27_247{left:715px;bottom:265px;letter-spacing:0.16px;}
#t28_247{left:1084px;bottom:265px;}
#t29_247{left:618px;bottom:229px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2a_247{left:618px;bottom:210px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2b_247{left:618px;bottom:190px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2c_247{left:618px;bottom:172px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2d_247{left:618px;bottom:152px;letter-spacing:0.16px;}
#t2e_247{left:988px;bottom:152px;}
#t2f_247{left:618px;bottom:116px;letter-spacing:-0.03px;word-spacing:-0.23px;}
#t2g_247{left:618px;bottom:96px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2h_247{left:618px;bottom:78px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2i_247{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_247{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_247{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_247{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_247{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_247{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_247{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_247{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts247" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg247Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg247" style="-webkit-user-select: none;"><object width="1210" height="935" data="247/247.svg" type="image/svg+xml" id="pdf247" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_247" class="t s0_247">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_247" class="t s1_247">© </span>
<span id="t3_247" class="t s0_247">(NCCN </span>
<span id="t4_247" class="t s1_247">© </span>
<span id="t5_247" class="t s0_247">), All rights reserved. NCCN Guidelines </span>
<span id="t6_247" class="t s1_247">® </span>
<span id="t7_247" class="t s0_247">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_247" class="t s2_247">NCCN Guidelines Version 4.2024 </span>
<span id="t9_247" class="t s2_247">Head and Neck Cancers </span>
<span id="ta_247" class="t s3_247">MS-106 </span>
<span id="tb_247" class="t s4_247">637. Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab </span>
<span id="tc_247" class="t s4_247">versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic </span>
<span id="td_247" class="t s4_247">head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, </span>
<span id="te_247" class="t s4_247">open-label, phase 3 study. Lancet 2019;393:156-167. Available at: </span>
<span id="tf_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/30509740</span><span id="tg_247" class="t s4_247">. </span>
<span id="th_247" class="t s4_247">638. Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for </span>
<span id="ti_247" class="t s4_247">recurrent squamous-cell carcinoma of the head and neck. N Engl J Med </span>
<span id="tj_247" class="t s4_247">2016;375:1856-1867. Available at: </span>
<span id="tk_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/27718784</span><span id="tl_247" class="t s4_247">. </span>
<span id="tm_247" class="t s4_247">639. Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or </span>
<span id="tn_247" class="t s4_247">without chemotherapy in recurrent or metastatic head and neck squamous </span>
<span id="to_247" class="t s4_247">cell carcinoma: updated results of the phase III KEYNOTE-048 study. J </span>
<span id="tp_247" class="t s4_247">Clin Oncol 2023;41:790-802. Available at: </span>
<span id="tq_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/36219809</span><span id="tr_247" class="t s4_247">. </span>
<span id="ts_247" class="t s4_247">640. Bossi P, Miceli R, Locati LD, et al. A randomized, phase 2 study of </span>
<span id="tt_247" class="t s4_247">cetuximab plus cisplatin with or without paclitaxel for the first-line </span>
<span id="tu_247" class="t s4_247">treatment of patients with recurrent and/or metastatic squamous cell </span>
<span id="tv_247" class="t s4_247">carcinoma of the head and neck. Ann Oncol 2017;28:2820-2826. Available </span>
<span id="tw_247" class="t s4_247">at: </span><span id="tx_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/28950305</span><span id="ty_247" class="t s4_247">. </span>
<span id="tz_247" class="t s4_247">641. Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and </span>
<span id="t10_247" class="t s4_247">cisplatin (TPEx) as first-line treatment in patients with recurrent or </span>
<span id="t11_247" class="t s4_247">metastatic (R/M) squamous cell carcinoma of the head and neck </span>
<span id="t12_247" class="t s4_247">(SCCHN): Final results of phase II trial GORTEC 2008-03 [abstract]. J Clin </span>
<span id="t13_247" class="t s4_247">Oncol 2012;30(Suppl 15):Abstract 5505. Available at: </span>
<span id="t14_247" class="t s5_247">http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5505</span><span id="t15_247" class="t s4_247">. </span>
<span id="t16_247" class="t s4_247">642. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of </span>
<span id="t17_247" class="t s4_247">the epidermal growth factor receptor antibody cetuximab and cisplatin for </span>
<span id="t18_247" class="t s4_247">recurrent and refractory squamous cell carcinoma of the head and neck. J </span>
<span id="t19_247" class="t s4_247">Clin Oncol 2005;23:5578-5587. Available at: </span>
<span id="t1a_247" class="t s5_247">http://www.ncbi.nlm.nih.gov/pubmed/16009949</span><span id="t1b_247" class="t s4_247">. </span>
<span id="t1c_247" class="t s4_247">643. Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination </span>
<span id="t1d_247" class="t s4_247">treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line </span>
<span id="t1e_247" class="t s4_247">treatment in patients with recurrent and/or metastatic squamous cell </span>
<span id="t1f_247" class="t s4_247">carcinoma of the head and neck (CSPOR-HN02). Ann Oncol </span>
<span id="t1g_247" class="t s4_247">2018;29:1004-1009. Available at: </span>
<span id="t1h_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/29408977</span><span id="t1i_247" class="t s4_247">. </span>
<span id="t1j_247" class="t s4_247">644. Guigay J, Auperin A, Fayette J, et al. Cetuximab, docetaxel, and </span>
<span id="t1k_247" class="t s4_247">cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment </span>
<span id="t1l_247" class="t s4_247">in patients with recurrent or metastatic head and neck squamous-cell </span>
<span id="t1m_247" class="t s4_247">carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, </span>
<span id="t1n_247" class="t s4_247">randomised, phase 2 trial. Lancet Oncol 2021;22:463-475. Available at: </span>
<span id="t1o_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/33684370</span><span id="t1p_247" class="t s4_247">. </span>
<span id="t1q_247" class="t s4_247">645. Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus </span>
<span id="t1r_247" class="t s4_247">cetuximab in patients with recurrent or metastatic head and neck </span>
<span id="t1s_247" class="t s4_247">squamous cell carcinoma: an open-label, multi-arm, non-randomised, </span>
<span id="t1t_247" class="t s4_247">multicentre, phase 2 trial. Lancet Oncol 2021;22:883-892. Available at: </span>
<span id="t1u_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/33989559</span><span id="t1v_247" class="t s4_247">. </span>
<span id="t1w_247" class="t s4_247">646. Chung CH, Li J, Steuer CE, et al. Phase II multi-institutional clinical </span>
<span id="t1x_247" class="t s4_247">trial result of concurrent cetuximab and nivolumab in recurrent and/or </span>
<span id="t1y_247" class="t s4_247">metastatic head and neck squamous cell carcinoma. Clin Cancer Res </span>
<span id="t1z_247" class="t s4_247">2022;28:2329-2338. Available at: </span>
<span id="t20_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/35344035</span><span id="t21_247" class="t s4_247">. </span>
<span id="t22_247" class="t s4_247">647. Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination </span>
<span id="t23_247" class="t s4_247">with cisplatin versus cisplatin monotherapy in patients with recurrent or </span>
<span id="t24_247" class="t s4_247">metastatic head and neck cancer: final results of a randomized, double- </span>
<span id="t25_247" class="t s4_247">blind, placebo-controlled, phase 3 study. Cancer 2012;118:4694-4705. </span>
<span id="t26_247" class="t s4_247">Available at: </span><span id="t27_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/22434360</span><span id="t28_247" class="t s4_247">. </span>
<span id="t29_247" class="t s4_247">648. Malhotra B, Moon J, Kucuk O, et al. Phase II trial of biweekly </span>
<span id="t2a_247" class="t s4_247">gemcitabine and paclitaxel with recurrent or metastatic squamous cell </span>
<span id="t2b_247" class="t s4_247">carcinoma of the head and neck: Southwest Oncology Group study </span>
<span id="t2c_247" class="t s4_247">S0329. Head Neck 2014;36:1712-1717. Available at: </span>
<span id="t2d_247" class="t s5_247">https://www.ncbi.nlm.nih.gov/pubmed/24166832</span><span id="t2e_247" class="t s4_247">. </span>
<span id="t2f_247" class="t s4_247">649. Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab </span>
<span id="t2g_247" class="t s4_247">versus extreme regimen as first-line treatment for recurrent/metastatic </span>
<span id="t2h_247" class="t s4_247">squamous cell carcinoma of the head and neck: the final results of </span>
<span id="t2i_247" class="t s6_247">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
